Quick Recap
Nests under Acute Respiratory Failure. Focus: Acute Exacerbation of COPD (AECOPD) requiring ICU-level care.
1. Definition
AECOPD = acute worsening of respiratory symptoms (dyspnea, cough, sputum volume/purulence) beyond normal day-to-day variation, requiring a change in therapy, in a patient with underlying COPD. ICU-level severity implies respiratory acidosis (pH <7.35, PaCO2 >45), signs of increased work of breathing, or need for ventilatory support.
2. Pathophysiology
Airway inflammation/bronchospasm and mucus hypersecretion -> increased airway resistance and dynamic hyperinflation (auto-PEEP) -> increased work of breathing -> respiratory muscle fatigue -> alveolar hypoventilation -> hypercapnic respiratory failure (pump failure superimposed on chronic V/Q mismatch). Triggers: respiratory viruses (most common), bacterial infection, environmental irritants, non-adherence to maintenance therapy, PE, pneumothorax, cardiac decompensation.
Dynamic hyperinflation is central: incomplete exhalation before the next breath raises intrinsic PEEP, increasing the work required to trigger a breath and predisposing to hemodynamic compromise with excessive ventilation/PEEP.
3. Immediate Stabilization (ABCDE)
Airway: assess ability to protect airway/clear secretions; if NIV fails or contraindicated, proceed to intubation without delay.
Breathing:
- Target SpO2 88-92% or PaO2 60-70 mmHg — avoid over-oxygenation (worsens V/Q mismatch, Haldane effect, suppresses hypoxic drive -> worsening hypercapnia)
- NIV (BiPAP) indicated for: acute respiratory acidosis (PaCO2 >45, pH <7.35) and/or increased work of breathing (accessory muscle use, retractions) — reduces intubation rate, mortality, hospital-acquired pneumonia, LOS
- Initial BiPAP settings: IPAP 10-15 cmH2O, EPAP 5-8 cmH2O; titrate IPAP by 2-3 cmH2O increments; patients on home NIV usually need a larger IPAP-EPAP delta than their baseline
- HFNC generally NOT recommended in AECOPD — unlike NIV, has not shown reduced intubation/mortality
- NIV contraindications: psychomotor agitation, severely depressed consciousness, large-volume emesis/aspiration risk, inability to manage secretions, severe facial deformity, persistent hemodynamic instability, cardiopulmonary arrest
- If IMV required: assist-control volume control, RR 12-14, Vt 6-8 mL/kg IBW, PEEP 5 cmH2O, lowest FiO2 for SpO2 88-92%; ventilate to patient's baseline/near-normal pH, NOT a "normal" PaCO2; adequate sedation for synchrony; watch for breath stacking/auto-PEEP
Circulation: hemodynamic compromise can occur from excessive intrathoracic pressure/auto-PEEP — if sudden hypotension post-intubation, disconnect circuit briefly to allow exhalation (auto-PEEP relief maneuver).
Disability: assess mental status — CO2 narcosis is a marker of severity and impending failure.
Exposure: look for pneumothorax (can mimic/precipitate exacerbation), cyanosis, peripheral edema (cor pulmonale).
Checklist:
4. Focused History
Baseline FEV1/severity, exacerbation frequency (>=2/year = high risk), prior ICU admissions/intubations, home oxygen or NIV use, smoking status, inhaler regimen/adherence, recent antibiotic courses, sputum change (volume/color/purulence), fever, chest pain (consider PE/pneumothorax/ACS as triggers), recent hospitalization (resistance risk), comorbid cardiac disease.
5. Examination + POCUS
Wheeze, prolonged expiratory phase, accessory muscle use, tripod positioning, pursed-lip breathing, paradoxical abdominal movement (fatigue sign), cyanosis, asterixis (CO2 narcosis), signs of cor pulmonale (raised JVP, peripheral edema).
POCUS: exclude pneumothorax (absent lung sliding) and pleural effusion as alternate/co-existing diagnoses; cardiac views to assess for concurrent cardiac decompensation/cor pulmonale.
6. Syndrome Identification
Hypercapnic respiratory failure ("pump failure") from lower airway obstruction/bronchospasm with dynamic hyperinflation — distinguish from primary cardiogenic or hypoxemic-predominant processes.
7. Differential Diagnosis
Tier | Examples |
Must exclude/co-triggers | Pneumothorax, PE, ACS/arrhythmia, pneumonia, acute heart failure |
Common | Viral URI trigger, bacterial bronchitis, medication non-adherence, environmental irritant exposure |
Must-not-miss | Occult sepsis, undiagnosed lung cancer causing obstruction |
8. Severity Assessment
GOLD exacerbation severity (mild/moderate/severe based on treatment intensity required); ABG-based respiratory acidosis grading; high-risk features for poor outcome: baseline FEV1 <50% predicted, >=2 exacerbations/year, hospitalization in prior 3 months, need for mechanical ventilation, chronic home O2 — these also guide antibiotic breadth (Section 11).
9. Investigations
- Bedside: ABG (mandatory, defines respiratory acidosis/severity), ECG (exclude arrhythmia/ACS), POCUS
- Labs: CBC, renal, electrolytes, BNP if cardiac cause uncertain
- Microbiology: sputum Gram stain/culture if high-risk features or ICU admission; blood cultures if febrile/septic
- Imaging: CXR (exclude pneumothorax, pneumonia, effusion, alternative diagnosis)
- Repeat: ABG after NIV initiation and at intervals per response
10. POCUS
Used primarily to exclude alternate/co-existing diagnoses (pneumothorax, effusion, cardiac dysfunction) rather than to characterize the primary obstructive process itself.
11. Evidence-Based Management
Bronchodilators: inhaled SABA (albuterol) +/- SAMA (ipratropium), nebulized preferred in acutely ill patients over MDI+spacer due to coordination difficulty. Continue home long-acting bronchodilators/ICS if already prescribed. Avoid IV methylxanthines (theophylline) — no efficacy advantage, significant toxicity.
Corticosteroids: prednisone 40 mg PO daily x5 days is non-inferior to 14 days (REDUCE trial) and preferred for most patients; oral and parenteral equally effective. For severe presentations requiring mechanical ventilation or persistent severe bronchospasm, some clinicians use higher initial doses (e.g., methylprednisolone ~125 mg/day tapered over 10-14 days) on an individualized basis — not routine practice. Balance against hyperglycemia, weakness, infection risk.
Antibiotics — indicated for most ICU-level AECOPD (benefit greatest in sickest patients):
- Standard risk (no high-risk features): macrolide, doxycycline, or amoxicillin-clavulanate
- High-risk (FEV1 <50% predicted, >=2 exacerbations/year, hospitalization in past 3 months, mechanical ventilation need, chronic home O2): 3rd-generation cephalosporin (e.g., ceftriaxone) or respiratory fluoroquinolone
- Pseudomonas risk factors (bronchiectasis, recent IV antibiotics, chronic oral steroids, prior Pseudomonas isolation): antipseudomonal agent required
Antivirals: oseltamivir for influenza-associated AECOPD regardless of symptom duration (zanamivir CONTRAINDICATED — risk of bronchospasm); remdesivir + dexamethasone if hypoxemic COVID-19-associated AECOPD (evidence evolving).
Not recommended / harmful: mucolytics (N-acetylcysteine), theophylline, routine chest physiotherapy — no benefit, possible harm. IV magnesium: equivocal evidence, not guideline-recommended though probably safe if used.
12. Organ Support
NIV/IMV per Section 3; avoid over-oxygenation; supportive fluid/nutrition management; treat concurrent cardiac decompensation if present.
13. Disease-Specific Therapy
See Section 11 in full (bronchodilators, steroids, antibiotics, antivirals). No disease-modifying acute therapy beyond these; focus is symptom/physiology control while the trigger resolves.
14. Consultation Matrix
Consultation | Trigger | Timing |
Pulmonology | Recurrent severe exacerbations, need for long-term NIV assessment | Within admission / 2-4 weeks post-discharge |
Cardiology | Concurrent cardiac decompensation/cor pulmonale | As needed |
ID | Resistant organism, treatment failure | 24-48h |
15. Monitoring Framework
Serial ABG post-NIV initiation and with clinical change; continuous SpO2 (target 88-92%); watch for NIV failure signs (rising PaCO2, falling GCS, hemodynamic instability) — do not delay intubation if failing. De-escalate NIV as acidosis/work of breathing resolves.
16. ICU Bundle Checklist (Daily)
17. Complications
NIV mask pressure injury, gastric insufflation/aspiration risk, pneumothorax (barotrauma, especially with auto-PEEP), post-intubation hemodynamic collapse from auto-PEEP, ICU-acquired weakness, steroid-related hyperglycemia/myopathy. Prevention: careful mask fitting, monitoring for auto-PEEP, shortest effective steroid course. Rescue: ventilator disconnect/exhalation maneuver for severe auto-PEEP-related hypotension; chest tube for pneumothorax.
18. Escalation & De-escalation
Escalate: rising PaCO2/falling pH despite NIV, declining mental status, hemodynamic instability, inability to clear secretions -> intubate.
Predictor of NIV failure: worsening (not improving) pH/PaCO2 within 1-2 hours of initiation.
Wean: resolving acidosis, decreasing FiO2/pressure requirements, improving mental status -> trial off NIV, then extended periods off, then discontinue.
19. ICU Discharge Criteria
Resolved/improved respiratory acidosis, stable on room air or baseline home O2 requirement, tolerating oral intake and maintenance inhalers, ambulatory/functional status near baseline, discharge inhaler regimen finalized (see Section 21).
20. Documentation & Medicolegal Checklist
21. Key Guidelines
GOLD (Global Initiative for Chronic Obstructive Lung Disease) report; ATS/ERS AECOPD guidance; REDUCE trial evidence underpinning 5-day steroid course.
22. Landmark Trials
- REDUCE trial: 5-day vs 14-day systemic corticosteroids in AECOPD — 5 days non-inferior, now standard.
- Trials establishing NIV superiority over IMV in AECOPD: reduced hospital-acquired pneumonia, shorter LOS, lower cost, improved mortality — AECOPD is the benchmark condition for NIV use in the ICU.
23. Controversies
No single antibiotic class has proven superiority — selection is individualized/stewardship-driven rather than protocolized. Optimal timing to assess for long-term nocturnal NIV after AECOPD remains unclear (reasonable to delay assessment 2-4 weeks post-resolution). Role of IV magnesium remains unresolved (probably safe, unproven benefit). HFNC role in AECOPD is not well established and is not currently recommended as NIV replacement.
24. Post-ICU / Discharge Bundle (unique to this protocol)
All patients should be discharged on long-acting maintenance therapy. For patients with >=1 severe exacerbation in the past year, triple therapy (LAMA + LABA + ICS) is superior to other regimens for preventing future exacerbations; LAMA-LABA alone is a reasonable alternative (e.g., recurrent pneumonia/mycobacterial infection/cost barriers to ICS). LABA-ICS alone should not generally be used. Confirm inhaler technique, smoking cessation counselling, influenza/pneumococcal vaccination updated, resting/walking O2 assessment 24-48h before discharge if hypoxemic during admission, consider long-term azithromycin or roflumilast for select patients with frequent exacerbations despite optimal inhaler therapy (outpatient initiation).
25. References
- Sattler L, Reynolds D. Noninvasive Ventilation. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 19).
- AECOPD chapter, Washington Manual of Critical Care, 4th ed, 2025 (Ch. 13).
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report, current edition.
- Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of COPD: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-2231.
- Chawla R, Todi S, eds. ICU Protocols: A Step-wise Approach. 2nd ed. Springer; 2020.